Advertisement

Topics

Latest "Kepler Cheuvreux Senkt Ziel Sanofi Euro" News Stories

00:03 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "Kepler Cheuvreux Senkt Ziel Sanofi Euro" found in our extensive news archives from over 250 global news sources.

More Information about Kepler Cheuvreux Senkt Ziel Sanofi Euro on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Kepler Cheuvreux Senkt Ziel Sanofi Euro for you to read. Along with our medical data and news we also list Kepler Cheuvreux Senkt Ziel Sanofi Euro Clinical Trials, which are updated daily. BioPortfolio also has a large database of Kepler Cheuvreux Senkt Ziel Sanofi Euro Companies for you to search.

Showing "Kepler Cheuvreux Senkt Ziel Sanofi Euro" News Articles 1–25 of 2,200+

Sunday 21st October 2018

Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics

The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent...  


Saturday 20th October 2018

sanofiaventis US LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummarySanofiAventis US LLC Sanofi US, a subsidiary of Sanofi is a drug company that discovers, develops and distributes various therapeutic solutions. The company provides prescription products, vaccines and other products. Sanofi US's vaccines include ActHIB, Adacel, DAPTACEL, Decavac, Fluzone, Imogam, IPOL, Menactra, Menomune, TheraCys, Typhim Vi, YFVAX, and Pentacel among others. The company's...

FDA genehmigt Dupixent von Sanofi als Asthma-Therapie

Von Maria Armental NEW YORK (Dow Jones)--Das Neurodermitis-Medikament Dupixent von Regeneron und Sanofi kann in den USA künftig auch zur Behandlung von Asthma eingesetzt werden. Die US-Gesundheits...


Global Drugs for Vulvovaginal Candidiasis Market Status and Outlook 20182025 [Report Updated: 14082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Sanofi, Regeneron's Dupixent garners FDA approval for moderate-to-severe asthma https://www.firstwordpharma.com/node/1598788  $SNY $REGN

Sanofi, Regeneron's Dupixent garners FDA approval for moderate-to-severe asthma https://www.firstwordpharma.com/node/1598788  $SNY $REGN

Friday 19th October 2018

Sanofi drug Dupixent wins FDA approval to treat asthma https://reut.rs/2yM8WAw 

Sanofi drug Dupixent wins FDA approval to treat asthma https://reut.rs/2yM8WAw 

Sanofi drug Dupixent wins FDA approval to treat asthma

France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

Sanofi: FDA approves asthma indication for Dupixent (dupilumab)

FDA approves asthma indication for Dupixent (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticostero...

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines...   

SanofiAventis Deutschland GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummarySanofiAventis Deutschland GmbH SanofiAventis, a subsidiary of Sanofi is a drug company that manufactures and markets prescription and over the counter drugs. The company's products include ultracain ds forte, sofra tulle classics, ultracain d without adrenaline, ultracain ds, zaltrap, cordarex, duoplavin, ultracain, vergentan ampoules, thymoglobuline, solian, vergentan tablets, uroxatral re...

RBC belässt Intel auf 'Sector Perform' - Ziel 55 Dollar

Das Analysehaus RBC hat die Einstufung für Intel auf "Sector Perform" mit einem Kursziel von 55 US-Dollar belassen. Dies schrieb Analyst Amit Daryanani in einer am Freitag vorliegenden Studie./bek...

American Express steigert Quartalsgewinn um 22 Prozent - Aktie zieht an

Im dritten Quartal stieg der Nettogewinn im Jahresvergleich um 22 Prozent auf 1,7 Milliarden Dollar (1,5 Mrd Euro), wie der Finanzkonzern am Donnerstag nach US-Börsenschluss in New York mitteilte. ...

Macquarie belässt ExxonMobil auf 'Underperform' - Ziel 70 Dollar

Die australische Investmentbank Macquarie hat die Einstufung für ExxonMobil auf "Underperform" mit einem Kursziel von 70 US-Dollar belassen. Dies geht aus einer am Freitag vorliegenden Studie des ...

EMA committee recommends approval of Sanofi's dengue virus vaccine Dengvaxia https://www.firstwordpharma.com/node/1598542  $SNY

EMA committee recommends approval of Sanofi's dengue virus vaccine Dengvaxia https://www.firstwordpharma.com/node/1598542  $SNY

Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up

Dengvaxia, the dengue vaccine from Sanofi that was suspended in the Philippines last year, is among six new products to......

STAT Plus: Pharmalittle: Europe is set to approve the Sanofi dengue vaccine; FDA panel chair disses panel vote

The chair of an FDA panel is defying a recommendation his own panel made to endorse a powerful opioid painkiller.

Sanofi receives positive CHMP opinion for dengue vaccine $SNY $SAN https://globenewswire.com/news-release/2018/10/19/1623971/0/en/Sanofi-receives-positive-CHMP-opinion-for-dengue-vaccine.html …

Sanofi receives positive CHMP opinion for dengue vaccine $SNY $SAN https://globenewswire.com/news-release/2018/10/19/1623971/0/en/Sanofi-receives-positive-CHMP-opinion-for-dengue-vaccine.html …

Sanofi Gets Positive CHMP Opinion For Dengue Vaccine

PARIS (dpa-AFX) - French drug giant Sanofi SA (SNYNF, SNY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion fo...

Pharmakonzern Sanofi berief neuen Chef für Österreich und Deutschland

Der französische Pharmakonzern Sanofi hat einen neuen Leiter für sein Geschäft in Österreich, Deutschland und der Schweiz berufen. Fabrizio Guidi übernehme den Posten zum 1. Jänner 2019 und sei auf...

Kepler Cheuvreux senkt Ziel für Merck KGaA auf 105 Euro - 'Buy'

Das Analysehaus Kepler Cheuvreux hat das Kursziel für Merck KGaA von 106 auf 105 Euro gesenkt, die Einstufung aber auf "Buy" belassen. Der frühe Erfolg des US-Namensvetters Merck & Co mit einem Ni...

Sanofi dengue vax gets EMA ok, despite Philippines scandal

Sanofi's dengue vaccine, Dengvaxia, has been recommended for approval in Europe by the European Medicines Agency's Committee for Medicinal Products for Human Use.

Pharmakonzern Sanofi beruft neuen Deutschland-Chef

Der Pharmakonzern Sanofi hat einen neuen Leiter für sein Deutschland-Geschäft berufen. Fabrizio Guidi übernehme den Posten zum 1. Januar 2019 und sei auf einer neu geschaffenen Stelle dann auch fü...

India Orthobiologics Market Outlook to 2025 [Report Updated: 02072018] Prices from USD $4995

India Orthobiologics Market Outlook to 2025SummaryGlobalData's new report, India Orthobiologics Market Outlook to 2025, provides key market data on the India Orthobiologics market. The report provides value, in millions of US dollars, volume in units and average prices USD within market categories Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics and Viscosupplementation...

Evotec-Aktie: Geht es weiter nach oben?

Mitte Mai ging die Evotec-Aktie in einen starken Aufwärtstrend über, der den Kurs Ende August in der Spitze bis auf knapp 23 Euro ansteigen ließ. Damit konnte auch das Doppel-Top aus dem Vorjahr be...

EU5 Orthobiologics Market Outlook to 2025 [Report Updated: 01082018] Prices from USD $5995

EU5 Orthobiologics Market Outlook to 2025SummaryGlobalData's new report, EU5 Orthobiologics Market Outlook to 2025, provides key market data on the EU5 Orthobiologics market. The report provides value, in millions of US dollars, volume in units and average prices USD within market categories Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics and Viscosupplementation.The r...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks